Amgen Inc. (AMGN) has been making quite a wave in recent market news as it shows impressive growth in both value and innovative developments. Famed investor,
Jim Cramer, strongly recommends AMGN as a vibrant addition to portfolios. Multiple financial advisors like
Oak Harvest Investment Services and
Advisors Capital Management LLC are significantly increasing their shareholdings in the biotech firm. Besides, this mass buying activity is being echoed by other parties, with
Banco Bilbao Vizcaya Argentaria S.A. and
M&G PLC also expanding their stakes. AMGN receives positive rating changes, with
Piper Sandler and
Scotiabank revising their rating upwards, suggesting optimistic price targets. AMGN's
Q3 financial results exceeded expectations, with business bolstered by positive responses to its new drugs. Investors are especially excited by the firm's obesity drug and its cholesterol drug. Market gains lift AMGN's share value as its profit margins reach 19%. However,
the National Pension Service and others have reduced their stakes. Pushing back against bearish narratives is news of AMGN beating Q3 expectations, raising 2025 guidance, and the success of the Repatha trial. The stock additionally shines due to robust revenue growth and advancements in cardiovascular studies.
Amgen AMGN News Analytics from Tue, 24 Jun 2025 07:00:00 GMT to Sat, 15 Nov 2025 13:28:19 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 5
